Chardan Capital Reaffirms Buy Rating for Avidity Biosciences (NASDAQ:RNA)
Chardan Capital reissued their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note published on Monday,Benzinga reports. The firm currently has a $65.00 price target on the biotechnology company’s stock. Other analysts have also recently issued research reports about the company. Scotiabank began coverage on Avidity Biosciences in a […]
Chardan Capital reissued their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note published on Monday,Benzinga reports. The firm currently has a $65.00 price target on the biotechnology company’s stock. Other analysts have also recently issued research reports about the company. Scotiabank began coverage on Avidity Biosciences in a […]
